For insulin and its analogues, GLP-1 receptor agonists, DDP4 inhibitors and SGLT2 inhibitors, MR study could use genetic instruments that are associated with the drug target protein or other downstream biomarkers to estimate the drug effect on RA risk when more relevant data emerge. This evidence concerns the gene INS and rheumatoid arthritis.